Has Omar Beckett received payments from drug or device companies?

Yes. Drug and device makers reported $3,832 in general payments to Omar Beckett across 99 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Omar Beckett did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Omar Beckett come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Omar Beckett

Pediatric Endocrinology · Miami, FLNPI 1013336874

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,596 of the $3,832 with a category attached, or 67.7%. 26 manufacturers reported payments, led by Medtronic at 47.2% of the total. Reporting peaked in 2020 at $1,789 and has fallen 69.0% since, to $554 in 2025.

$3,832in general payments, 2019–2025

Across 99 payments — averaging $38.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$2K
Eton Pharmaceuticals, Inc.$225
Novo Nordisk$206
Sanofi-aventis U.S. LLC$181
AbbVie$159
Azurity Pharmaceuticals, Inc.$120
plus $1K from 20 others

What the payments were for

Travel & lodging$1,23732%
Food & beverage$2,59668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	13	$1,807
Eton Pharmaceuticals, Inc.	3	$225
Novo Nordisk	11	$206
Sanofi-aventis U.S. LLC	10	$181
AbbVie	9	$159
Azurity Pharmaceuticals, Inc.	6	$120
Mannkind Corporation	1	$108
Ascendis Pharma Endocrinology Inc	4	$100
Neurocrine Biosciences, Inc.	3	$90
Xeris Pharmaceuticals, Inc.	4	$86
AstraZeneca	3	$83
Tandem Diabetes Care, Inc.	4	$80
Dexcom, Inc.	4	$78
BETA Bionics, Inc.	4	$73
Pfizer	3	$57
Abbott	2	$49
Rhythm Pharmaceuticals, Inc.	2	$48
Kyowa Kirin, Inc.	2	$47
Lifescan, Inc.	2	$43
Amphastar Pharmaceuticals, Inc.	2	$43
Soleno Therapeutics, Inc.	1	$41
Tolmar Pharmaceuticals, Inc.	2	$34
Sequel Med Tech, LLC	1	$21
Lilly USA, LLC	1	$20
IBSA Pharma Inc.	1	$19
Boston Scientific	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,832 in reported general payments places this provider in the 65th percentile of 102 pediatric endocrinology providers in Florida.

See all pediatric endocrinology providers in Florida →

Other pediatric endocrinology in Miami

Alejandro DiazMiami$101K
Andrea GranadosMiami$19K
Adriana Carrillo-IreguiMiami$19K
Janine SanchezMiami$18K
Joshua TarkoffMiami$9K
Luis Gonzalez-MendozaMiami$9K
Pedro Pagan BanchsMiami$4K
Carmen Bustamante EscobarMiami$3K
Jonanlis Ramirez AlcantaraMiami$2K
Marco DanonMiami$1K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →